Iolanda Vendrell
PhD
Technologly Lead, Discovery Proteomics SRF
Iolanda Vendrell joined the Discovery Proteomics Facility at the University of Oxford in 2015, as a senior scientist in Biological Mass Spectrometry. She currently is the Technology Lead. She studied Biochemistry at the University of Barcelona and holds a PhD in Biochemistry (in the Neuroscience program) by the same University. Her interest in Proteomics and Mass Spectrometry started during her PhD. In 2007, she moved to the UK where she has been working in Proteomics labs in both Academia and Biotech companies. Over the years, Iolanda has developed an extensive expertise in using bottom up-proteomics for general discovery projects, biomarker discovery for clinical samples and post-translational modifications. Currently, one of her interest focuses on developing and implementing high-throughput proteomics platforms for clinical and non-clinical projects.
Recent publications
-
Cyclin F–EXO1 axis controls cell cycle–dependent execution of double-strand break repair
Journal article
Yang H. et al, (2024), Science Advances, 10
-
High-throughput mass spectrometry maps the sepsis plasma proteome and differences in patient response
Journal article
Mi Y. et al, (2024), Science Translational Medicine, 16
-
Oncogenic mutations of KRAS modulate its turnover by the CUL3/LZTR1 E3 ligase complex
Journal article
Damianou A. et al, (2024), Life Science Alliance, 7, e202302245 - e202302245
-
Proximity proteomics reveals UCH-L1 as an essential regulator of NLRP3-mediated IL-1β production in human macrophages and microglia.
Journal article
Liang Z. et al, (2024), Cell reports, 43
-
Data‐independent acquisition proteomics of cerebrospinal fluid implicates endoplasmic reticulum and inflammatory mechanisms in amyotrophic lateral sclerosis
Journal article
Dellar ER. et al, (2024), Journal of Neurochemistry, 168, 115 - 127